Correction to: Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression

Cecropin-Loaded Zeolitic Imidazolate Framework Nanoparticles with High Biocompatibility and Cervical Cancer Cell Toxicity

“…HeLa cells were incubated with the indicated concentrations of ZIF-8 NPs, free CEC, CEC@ZIF-8 NPs, vehicle (negative control), or cisplatin (positive control) for 24 h. Survival rates exceeded 80% at all doses of ZIF-8 NPs compared to negative controls ( Figure 7 a), indicating that ZIF-8 NPs possess negligible cytotoxicity within this concentration range. This result is consistent with previous studies that demonstrated the biocompatibility and safety of ZIF-8 NPs as drug nanocarriers for cancer therapy [ 48 , 49 ]. Incorporation of CEC into ZIF-8 NPs increased cytotoxicity compared to equivalent concentrations of free CEC with 80 μg/mL ( p < 0.05) ( Figure 7 b), suggesting that the nanocarrier greatly enhances CEC effective endocytosis and accumulation into the cytoplasm [ 43 ].…”

“…ure 7a), indicating that ZIF−8 NPs possess negligible cytotoxicity within this concentration range. This result is consistent with previous studies that demonstrated the biocompatibility and safety of ZIF−8 NPs as drug nanocarriers for cancer therapy [48,49]. Incorporation of CEC into ZIF−8 NPs increased cytotoxicity compared to equivalent concentrations of free CEC with 80 µg/mL (p < 0.05) (Figure 7b), suggesting that the nanocarrier greatly enhances CEC effective endocytosis and accumulation into the cytoplasm [43].…”